Thursday, March 14, 2019 Targovax grants Zelluna an FTO license to Targovax patents and know-how to further enable development of Zelluna’s mutant RAS T-cell receptor therapies Targovax and Zelluna intend to collaborate on additional discovery and development of novel mutant RAS T ... read more

Lund, Sweden, 08.00 CET, March 13, 2019 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, today announced the launch of BONIFY™, a demineralized bone matrix (DBM) product line, expanding the company’s product portfolio in the US market. BONIFY will... read more

~ Extended Evaluation Phase Meets Objective of Showing Positive Long-Term Benefit-Risk Profile of RECORLEV™ (levoketoconazole) ~ ~ Favorable Liver-Related Findings: No Patients Experienced an Increase in Either Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) of Greater than Thr... read more

STOCKHOLM, SWEDEN – 11 March 2019: Modus Therapeutics AB, a company developing innovative treatments for patients with high unmet medical needs and a focus on sickle cell disease (SCD), announces the appointment of Mats Blom as Chief Financial Officer (CFO). Mr Blom joins Modus Therapeutics on ... read more

DUBLIN, Ireland and TREVOSE, Pa., March 04, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announ... read more